Target intelligence / Profile preview

Proteasome subunit (None)

Target
None
Molecular classification
Enzyme, Multisubunit protein complex
01

Overview

The proteasome is a large, multisubunit protease complex essential for regulated protein degradation in eukaryotic cells. It exists primarily as the 26S proteasome, composed of a 20S core particle and one or two 19S regulatory particles. The 20S core contains multiple alpha and beta subunits arranged in stacked rings, with three main catalytic beta subunits (β1 with caspase-like, β2 with trypsin-like, and β5 with chymotrypsin-like activity) responsible for degrading most polyubiquitinated proteins. The proteasome is a central player in protein homeostasis, cell cycle regulation, apoptosis, immune surveillance, and neural signaling. Proteasome inhibition is an established cancer therapy mechanism, but the generic term “proteasome subunit” is imprecise as there are at least fourteen core subunits, each with distinct names and functions. For drug targeting and annotation, it is important to specify the unique subunit(s) of interest. Note: The use of “Proteasome subunit” as a generic target is not recommended due to lack of specificity. Established reference requires precise names for each individual subunit involved.

02

Mechanism of action

Inhibition of proteolytic activity of specific catalytic subunits (primarily β5, and to a lesser extent β1 and β2), blocking degradation of polyubiquitinated proteins and thereby inducing apoptosis in rapidly dividing cells. Prevention of degradation of regulatory proteins involved in cell cycle and apoptosis (stabilizing p53, cyclins, etc.). Modulation of NF-κB pathway via stabilization of its inhibitor IκB.

03

Biological functions

Protein degradation (proteolysis)Regulation of cell cycleApoptosisImmune response (including antigen presentation)Cellular homeostasis and stress responseRegulation of transcription factors
04

Disease associations

CancerNeurodegenerative diseaseInflammationInfectionOther (proteostasis-related disorders)
05

Safety considerations

Hematologic toxicities (especially thrombocytopenia and neutropenia)Peripheral neuropathy (notably with bortezomib)Increased risk of infections (due to effects on immune proteasome and antigen presentation)Proteasome inhibition may impair normal cell function and lead to off-target tissue toxicity, including renal and cardiac effects
06

Interacting drugs

Bortezomib

5 more in the full profile.

07

Biomarkers

Proteasome activity assays (measuring chymotrypsin/trypsin/caspase-like activity in cells/tissues)Expression or mutation analysis of specific subunits (e.g. PSMB5)Ubiquitinated protein levels as pharmacodynamic readout

Beyond the preview

Go deeper on Proteasome subunit (None).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proteasome subunit (None).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call